Shoham Shmuel
Department of Medicine, Johns Hopkins School of Medicine, 1830 East Monument St., Room 447, Baltimore, MD, 21205, USA.
Curr Top Microbiol Immunol. 2024 Aug 9. doi: 10.1007/82_2024_272.
COVID-19 convalescent plasma (CCP) is an important therapeutic option for immunocompromised patients with COVID-19. Such patients are at increased risk for serious complications of infection and may also develop a unique syndrome of persistent infection. This article reviews the rationale for CCP utilization in immunocompromised patients and the evidence for its value in immunosuppressed patients with both acute and persistent COVID-19. Both historical precedence and understanding of the mechanisms of action of antibody treatment support this use, as do several lines of evidence derived from case series, comparative studies, randomized trials, and systematic reviews of the literature. A summary of recommendations from multiple practice guidelines is also provided.
新冠康复者血浆（CCP）是免疫功能低下的新冠肺炎患者的一种重要治疗选择。这类患者发生感染严重并发症的风险增加，也可能出现持续性感染的独特综合征。本文综述了在免疫功能低下患者中使用CCP的理论依据，以及其在急性和持续性新冠肺炎免疫抑制患者中的价值证据。历史先例和对抗体治疗作用机制的理解均支持这种应用，来自病例系列、比较研究、随机试验及文献系统评价的多项证据也是如此。还提供了多个实践指南的建议总结。
